About Inimmune
Inimmune is a company based in Missoula (United States) founded in 2016 by Kendal Ryter.. Inimmune has raised $22 million across 3 funding rounds from investors including NIH, HHS and Two Bear Capital. The company has 35 employees as of December 31, 2021. Inimmune offers products and services including INI-2004, INI-4001, and TRAC478. Inimmune operates in a competitive market with competitors including BeiGene, Serum Institute of India, TScan Therapeutics, Vir Biotechnology and BioNTech, among others.
- Headquarter Missoula, United States
- Employees 35 as on 31 Dec, 2021
- Founders Kendal Ryter
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Inimmune Corp.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$22 M (USD)
in 3 rounds
-
Latest Funding Round
$22 M (USD), Series A
Jul 10, 2020
-
Investors
NIH
& 2 more
-
Employee Count
35
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inimmune
Inimmune offers a comprehensive portfolio of products and services, including INI-2004, INI-4001, and TRAC478. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
TLR4 agonist for treating allergic rhinitis in clinical trials
TLR7/8 agonist for cancer treatment with checkpoint inhibitors
Adjuvant system for enhancing vaccine responses
Unlock access to complete
Unlock access to complete
Funding Insights of Inimmune
Inimmune has successfully raised a total of $22M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $22 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $22.0M
-
First Round
First Round
(09 Feb 2018)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Series A - Inimmune | Valuation | Two Bear Capital |
|
| Jul, 2020 | Amount | Grant - Inimmune | Valuation |
investors |
|
| Feb, 2018 | Amount | Grant - Inimmune | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Inimmune
Inimmune has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Two Bear Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Two Bear Capital is focused on investing in innovative founders.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Inimmune
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Inimmune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Inimmune Comparisons
Competitors of Inimmune
Inimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Serum Institute of India, TScan Therapeutics, Vir Biotechnology and BioNTech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare respiratory diseases are developed by Savara Pharma.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Inimmune
Frequently Asked Questions about Inimmune
When was Inimmune founded?
Inimmune was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is Inimmune located?
Inimmune is headquartered in Missoula, United States. It is registered at Missoula, Montana, United States.
Is Inimmune a funded company?
Inimmune is a funded company, having raised a total of $22M across 3 funding rounds to date. The company's 1st funding round was a Grant of $1.19M, raised on Feb 09, 2018.
How many employees does Inimmune have?
As of Dec 31, 2021, the latest employee count at Inimmune is 35.
What does Inimmune do?
Inimmune was founded in 2016 in Missoula, United States, within the biotechnology sector. Focus is placed on discovering and developing innate immune receptor agonists and antagonists to address food allergies, allergic rhinitis, and autoimmune disorders. The pipeline encompasses preclinical vaccines for food allergies, modulators for rhinitis, and discovery-stage TLR antagonists for Th1Th2Th17-mediated conditions. Fee-based contract services, including drug formulation, analytical chemistry, immunology, and chemical synthesis, are offered to pharmaceutical partners.
Who are the top competitors of Inimmune?
What products or services does Inimmune offer?
Inimmune offers INI-2004, INI-4001, and TRAC478.
Who are Inimmune's investors?
Inimmune has 3 investors. Key investors include NIH, HHS, and Two Bear Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.